Monograph
L01AX03 - Temozolomide |
Not porphyrinogenic |
NP |
Rationale
Non-hepatic metabolism. Temozolomide lacks CYP-affinity. Side effects as nausea, anorexia and vomiting may be potentially porphyrinogenic through reduction in caloric intake.
Chemical description
Triazene derivative.
Therapeutic characteristics
Temozolomide is an alkylating antineoplastic agent used to treat newly diagnosed glioblastoma multiforme, recidivating or therapy resistent malignant glioma and refractory anaplastic astrocytoma. Given orally in combination with radiation therapy.
Common adverse reactions of temozolomide that can be confused with an acute porphyric attack are nausea, vomiting, obstipation, myopathy, paraesthesia.
Hepatic exposure
Not significant
Metabolism and pharmacokinetics
Rapid nonenzymatic hydrolysis hydrolysis at physiological pH to metabolites that undergo renal excretion. Distributed to brain giving rise to cytotoxic metabolites via spontaneous hydrolysis, where metabolites undergo renal clearence.
IPNet drug reports
No.
References
| # |
Citation details |
PMID |
|---|
| * | Scientific articles |
| 1. |
Rendic, S. Summary of information on human CYP enzymes: human P450 metabolism. Drug metabolism reviews 2002; 34(1&2), 83-448.
|
11996015 |
| * | Drug reference publications |
| 2. |
Sweetman SC, editor. Martindale: The complete drug reference. Busulfan. Pharmaceutical Press 2009.
|
|
| * | Other sources |
| 3. |
Swedish National Formulary. FASS. Temodal. www.fass.se (product leaflet).
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
Latvia
Serbia
